Economic evaluation of highly purified menotropin compared with recombinant follicle- stimulating hormone in assisted reproduction Adam Lloyd, M.Phil.,

Slides:

Advertisements

Similar presentations

What’s the delay? A qualitative study of women’s experiences of reaching a diagnosis of endometriosis Karen Ballard, Ph.D., Karen Lowton, Ph.D., Jeremy.

Advertisements

HP-HMG versus rFSH in treatments combining fresh and frozen IVF cycles: success rates and economic evaluation Jaro Wex-Wechowski, Ahmed M. Abou-Setta,

Evaluation of basal estradiol levels in assisted reproductive technology cycles2 John L Frattarelli, M.D., Paul A Bergh, M.D., Michael R Drews, M.D.,

The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition Lorraine Dennerstein,

Bjørn Bay, M. D. , Erik Lykke Mortensen, M. Sc

The predictive value for in vitro fertility delivery rates is greatly impacted by the method used to select the threshold between normal and elevated.

Michael M. Alper, M.D. Fertility and Sterility

Janet Kwee, M. D. , Roel Schats, M. D. , Ph. D. , Joseph McDonnell, M

The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation.

A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer

Neohormones as biomarkers of reproductive health

Growth rates of ovarian follicles during natural menstrual cycles, oral contraception cycles, and ovarian stimulation cycles Angela R. Baerwald, Ph.D.,

Follicular-phase ovarian follicular fluid and plasma cytokine profiling of natural cycle in vitro fertilization patients N. Ellissa Baskind, M.B.Ch.B.,

Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging Siobán D. Harlow,

Antimüllerian hormone levels and antral follicle count as prognostic indicators in a personalized prediction model of live birth Scott M. Nelson, M.R.C.O.G.,

Hongxia Li, M. D. , Jiangang Chen, M. D. , James W Overstreet, M. D

Medical treatment of ectopic pregnancy: a committee opinion

Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization.

A differential cytokine expression profile is induced by highly purified human menopausal gonadotropin and recombinant follicle-stimulating hormone in.

The relative contribution of assisted reproductive technologies and ovulation induction to multiple births in the United States 5 years after the Society.

Modified natural cycle in in vitro fertilization

Hakan Cakmak, M. D. , Audra Katz, R. N. , Marcelle I. Cedars, M. D

A comparison of blood spot vs

Randomized, controlled pilot trial of natural versus hormone replacement therapy cycles in frozen embryo replacement in vitro fertilization Ginny Mounce,

A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data

Evaluating the performance of serum antimullerian hormone concentration in predicting the live birth rate of controlled ovarian stimulation and intrauterine.

Assisted reproductive technology in the United States: 1999 results generated from the American Society for reproductive medicine/society for assisted.

Differences in gene expression of granulosa cells from women undergoing controlled ovarian hyperstimulation with either recombinant follicle-stimulating.

Remembering Gary D. Hodgen, Ph.D.: 1943–2005

Chao-Chin Hsu, M. D. , Ph. D. , Hsin-Chih Kuo, Ph. D

A prospective randomized clinical trial of differing starter doses of recombinant follicle- stimulating hormone (follitropin-β) for first time in vitro.

Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection.

Looking back: egg donors' retrospective evaluations of their motivations, expectations, and experiences during their first donation cycle Nancy J. Kenney,

Efficacy and safety of frozen-thawed embryo transfer in women aged 35 to 42 years from the PURSUE randomized clinical trial Robert Boostanfar, M.D.,

Clinical Assessment of Recombinant Human Follicle-Stimulating Hormone in Stimulating Ovarian Follicular Development Before In Vitro Fertilization fn1

A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin.

Tomer Singer, M. D. , David H. Barad, M. D. , M. S

Management of tubal ectopic pregnancy: methotrexate and salpingostomy are preferred to preserve fertility Stephanie Beall, M.D., Ph.D., Alan H. DeCherney,

Cost-effectiveness analysis comparing continuation of assisted reproductive technology with conversion to intrauterine insemination in patients with low.

Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D.

Effect of letrozole at 2. 5 mg or 5

Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis Rina Agrawal,

Treatment of male idiopathic infertility with recombinant human follicle-stimulating hormone: a prospective, controlled, randomized clinical study Carlo.

Endometrial morphology and modulation of hormone receptors during ovarian stimulation for assisted reproductive technology cycles Laura Detti, M.D.,

Delayed orgasm and anorgasmia

Tania Luisa Stevenson, M.B.Ch.B., Hany Lashen, F.R.C.O.G.

Concentrations of inhibins and activin in women undergoing stimulation with recombinant follicle-stimulating hormone for in vitro fertilization treatment

A longitudinal study of the effects of free testosterone and other psychosocial variables on sexual function during the natural traverse of menopause

Live babies born per oocyte retrieved in a subpopulation of oocyte donors with repetitive reproductive success J. Ryan Martin, M.D., Jason G. Bromer,

Predictive usefulness of cycle day 10 follicle-stimulating hormone level in a clomiphene citrate challenge test for in vitro fertilization outcome in.

A double-blind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle-stimulating hormone in women undergoing in vitro.

Effectiveness of highly purified human menopausal gonadotropin vs

Regulation of assisted reproductive technologies in the United States

Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis.

Analysis of the cost effectiveness of recombinant versus urinary follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection.

Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.

Current evaluation of amenorrhea

A combined analysis of data to identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism treated with recombinant human.

Serum anti-Mullerian hormone dynamics during stimulated cycles by aromatase inhibitor anastrozole and clomiphene citrate in women with infertility H.-H.

Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function David H. Barad, M.D., M.S., Andrea Weghofer,

Effectiveness of human menopausal gonadotropin versus recombinant follicle- stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive.

What’s the delay? A qualitative study of women’s experiences of reaching a diagnosis of endometriosis Karen Ballard, Ph.D., Karen Lowton, Ph.D., Jeremy.

Early menopause in mothers of children with Down syndrome?

Conversion from assisted reproductive technology to intrauterine insemination in low responders: Is it advantageous? John M. Norian, M.D., Eric D. Levens,

Use of recombinant human chorionic gonadotropin in ovulation induction

Randomized, controlled pilot trial of natural versus hormone replacement therapy cycles in frozen embryo replacement in vitro fertilization Ginny Mounce,

Anitha Pankajakshy, M.Sc., M.Phil., Indira Madambath, Ph.D.

Basal antral follicle number and mean ovarian diameter predict cycle cancellation and ovarian responsiveness in assisted reproductive technology cycles2

Low-dose human chorionic gonadotropin therapy can improve sensitivity to exogenous follicle-stimulating hormone in patients with secondary amenorrhea

Oocyte retrieval timing based on spontaneous luteinizing hormone surge during natural cycle in vitro fertilization treatment Daniel Bodri, M.D., M.Sc.,

Presentation transcript:

Economic evaluation of highly purified menotropin compared with recombinant follicle- stimulating hormone in assisted reproduction Adam Lloyd, M.Phil., Richard Kennedy, M.B.Ch.B., D.A., F.R.C.O.G., Julia Hutchinson, M.Sc., Will Sawyer, Ph.D. Fertility and Sterility Volume 80, Issue 5, Pages 1108-1113 (November 2003) DOI: 10.1016/S0015-0282(03)02185-X

Figure 1 Sequence of visits associated with assisted reproduction in the study. Lloyd. Economics of assisted reproduction. Fertil Steril 2003. Fertility and Sterility 2003 80, 1108-1113DOI: (10.1016/S0015-0282(03)02185-X)

Figure 2 Sensitivity analysis of the relationship between discount rates for study medication and cost per cycle. Lloyd. Economics of assisted reproduction. Fertil Steril 2003. Fertility and Sterility 2003 80, 1108-1113DOI: (10.1016/S0015-0282(03)02185-X)